One of the most popular treatments for thalassaemia is the administration of an iron-chelating drug via a portable infusion pump.
Thalassaemia (from the Greek "anaemia of the sea", as it is widespread mainly in coastal regions) is a hereditary disease consisting of a genetic defect in the formation of haemoglobin, whose role is to transport oxygen via iron molecules.
There are several types of anaemia present mainly in the countries of the Mediterranean, equatorial Africa and Southeast Asia. Currently, the disease is widespread almost all over the world due to the migration of subjects affected by the disease.
Beta thalassemia major, or Cooley's disease, is the most severe form of Mediterranean anaemia, transmitted when both parents carry a gene that is defective in the synthesis of the beta haemoglobin chain.
The thalassaemia subject has a bone marrow that does not produce the right amounts of haemoglobin.
To survive, the patient must resort to continuous blood transfusions, which cause an exaggerated accumulation of iron in the tissues.
This excess can cause severe harm to the body (heart failure, diabetes, liver cirrhosis, etc).
One of the fundamental therapies for treating this pathology is based on iron-chelating drugs administered subcutaneously through an infusion pump, which bind the iron and allow it to be eliminated.
The objective is to keep the body's iron levels below the toxicity threshold, improving the quality of life and life expectancy of patients.
The first infusion pump designed by Canè was built following a request from the Thalassaemia Centre of the University of Turin for the administration of Desferal, an iron-chelating drug.
The device was initially a syringe pusher and over time the company developed a new miniaturised model: the Crono T infusion pump.
The therapy does not require surgical interventions on the patient, thus proving to be a minimally invasive solution.
The drug must be administered daily over 8-12 hours subcutaneously.
The Crono T infusion pump can be used with any infusion set for subcutaneous use.
The small size and light weight (127 g) of the infusion pump make it ideal for home use.
The infusion pump can be worn by means of a fabric cord, or at the waist with the aid of a case (similar to that for mobile phones), ensuring discretion during the course of therapy.
The products described in this website are covered by the EU declaration of conformity, so they are intended for the EU market, with the declared intended purpose.
For non-EU markets such as the US, please contact CANÈ S.p.A. to identify the correct product and the corresponding destination of use.